---
document_datetime: 2025-09-25 14:18:02
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/revolade-pam-0000274861-epar-assessment-report_en.pdf
document_name: revolade-pam-0000274861-epar-assessment-report_en.pdf
version: success
processing_time: 16.7890228
conversion_datetime: 2025-12-22 17:42:39.014599
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 August 2025 EMADOC-1700519818-2460734 Human Medicines Division

## Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006

## Revolade

Eltrombopag

Procedure no:

EMA/PAM/0000274861

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Current step                                               | Description                                                | Planned date                                               | Actual Date                                                |
|                                                            | CHMP Rapporteur AR                                         | 28 July 2025                                               | 29 July 2025                                               |
|                                                            | CHMP comments                                              | 11 August 2025                                             | 11 August 2025                                             |
|                                                            | Updated CHMP Rapporteur AR                                 | 14 August 2025                                             | 14 August 2025                                             |
|                                                            | CHMP outcome                                               | 21 August 2025                                             | 21 August 2025                                             |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Introduction ............................................................................................5                   |
|---------------------------------------------------------------------------------------------------------------------------------|
| 2. Scientific discussion ................................................................................5                      |
| 2.1. Information on the development program ...............................................................5                    |
| 2.2. Information on the pharmaceutical formulation used in the study...............................5                            |
| 2.3. Clinical aspects ....................................................................................................5     |
| 2.3.1. Introduction......................................................................................................5      |
| 2.3.2. Clinical study ....................................................................................................6     |
| Clinical study number and title .....................................................................................6          |
| Description.................................................................................................................6   |
| Results ......................................................................................................................8 |
| 2.3.3. Discussion on clinical aspects ............................................................................16            |
| 3. Rapporteur's overall conclusion and recommendation ..........................17                                              |

<div style=\"page-break-after: always\"></div>

## List of abbreviations used in the text

AA Aplastic anemia

AE Adverse event

AESI Adverse event of special interest

AKI Acute kidney injury

ALG Anti-lymphocyte immunoglobulin

ALT Alanine aminotransferase

AML Acute myeloid leukemia

AST Aspartate aminotransferase

ATG Anti-thymocyte globulin

CHR Chromosone

CR Complete response

CsA Cyclosporine A

CSR Clinical study report

ECG Electrocardiograms

EOT End of treatment

GGT Gamma-glutamyltransferase increased

G-CSF Granulocyte colony-stimulating factor

h-ATG Horse anti-thymocyte globulin

HSCT Hematopoietic stem cell transplantation

IST

Immunosuppressive therapy

KM Kaplan-Meier

LPLV Last participant last visit

OS Overall survival

PD Protocol deviation

PK Pharmacokinetic

PR Partial response

PT Preferred term

r-ATG Rabbit anti-thymocyte globulin

RBC Red blood cell

SAA Severe aplastic anemia

SOC System organ class

TPO-R Thrombopoietin receptor

VSAA Very severe aplastic anemia

<div style=\"page-break-after: always\"></div>

## 1. Introduction

On 23 May 2025, the MAH submitted a completed paediatric study for Revolade, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended.

A short critical expert overview has also been provided.

Study CETB115G2201 was an Interventional, non-randomized, open label, multi-center, Phase II study to assess the safety and efficacy of eltrombopag in combination with rabbit anti-thymocyte globulin (rATG) and cyclosporine A (CsA) in East-Asian patients with treatment naive severe aplastic anemia. Eight of the 36 total patients were children.

The critical expert overview presents paediatric data collected and reported from the final clinical study report for study CETB115G2201.

No changes to the paediatric information of the current EU Summary of Product Characteristics (SmPC) are proposed based on the results of this study.

## 2. Scientific discussion

## 2.1. Information on the development program

The MAH stated that CETB115G2201 is a stand -alone study, which enrolled 36 total patients. Of them, 8 were paediatric patients under 18 yrs.

## 2.2. Information on the pharmaceutical formulation used in the study

Eltrombopag tablets were supplied to the Investigators by Novartis at dose strengths of 12.5 mg and 25 mg (for more information see Table 2, study treatment batch numbers in next section of this report).

## 2.3. Clinical aspects

## 2.3.1. Introduction

The MAH submitted a final report for:

- Study G2201 (CETB115G2201; REACTS): A non-randomized, open label, multi-center, Phase II study to assess the safety and efficacy of eltrombopag in combination with rabbit antithymocyte globulin (r-ATG) and cyclosporine A (CsA) in East-Asian patients with treatment naive severe aplastic anemia.

The clinical overview submitted by the company summarizes and discuss the results of the efficacy and safety for paediatric participants &lt;18 years of age (N=8).

The results of the pharmacokinetics assessments involving paediatric participants are not within the scope of this report. In addition, efficacy and safety endpoints analysis that were not specifically conducted for the subgroup of paediatric participants &lt;18 years of age but limited to only the overall population enrolled in the study are beyond the scope of the Company's report.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Clinical study

## Clinical study number and title

## Description

Study G2201 was a non-randomized, open label, single arm, multi-center, Phase II study. This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment-naive East-Asian adult and paediatric participants with SAA in Chinese Mainland, Japan, Korea, and Taiwan (Province of China). The study included 3 parts, a core treatment part from Day 1 to Week 26 (the time for primary endpoint assessment), an extension part up to Week 52 for responders (who met the CR or PR criteria at Week 26) and a long-term follow-up part for all participants enrolled.

Figure 1 represents the study design and Table 1 includes all details about study aim, objectives, rationale of study design, study population, inclusion/exclusion criteria, treatments and data analysis. Table 2 includes details about study treatment batch numbers.

Figure 1. Schematic of study design

<!-- image -->

Source:[Study G2201Final analysis CSR-Figure 9-1]

<div style=\"page-break-after: always\"></div>

Table 1. Summary of study design

<!-- image -->

| Purpose          | Thepurposeof thisstudywastoevaluatetheeficacyandsafetyofeltrombopagwhenadded tor-ATGandCsAintrealmentnaiveEast-AsianadultandpediatricparticipantswithSAA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Thepurposeof thisstudywastoevaluatetheeficacyandsafetyofeltrombopagwhenadded tor-ATGandCsAintrealmentnaiveEast-AsianadultandpediatricparticipantswithSAA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Objective(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Endpoint(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Primary          | Toevaluatetheefficacyofeltrombopagin combinationwithr-ATGandCsAintermsof completeresponserale at 6months inEast- AsianpatieniswithtreatmentnaiveSAA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | CRrateatWeek28(6months)after startingthestudytreatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Secondary        | To evaluate completeresponserate at 3.12monthsandyearly after                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CRrateat Week13(3months).Week52 （12months)andyearly after                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                  | Toevaluateoverallresponserate at 3.6, 12monthsandyearlyafter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Overallresponse(CR+PR)rateatWeek13 (3months).Week26(6months).Week52 (12months)andyearlyafter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                  | Toevaluatedurationofresponse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Timefromthedateofthestartofresponse to thedateofrelapseordeath,whichever oocursfirstatanytimeduningthestudy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                  | Toevaluateoverall survival                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Timefromthedateoffirstdoseofstudy treatmenttothedateofdeath OverallsurvivalrateatWeek26.Week52 andyearyaiter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                  | Toevaluatetheneedfortransfusion(packed RBCunits andplateletunits)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Timefromthemostrecent transfusion toWeek13andWeek26 Proportionof participantswho become(plateletRBC)transfusion independent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                  | Toevaluatesafetyandtolerabilityof eltrombopagincombinationwithr-ATGandCsA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | FrequencyandseverityofAEsSAEs,vital signs,electrocardliogramandlaboratory abnomalities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                  | Toevaluateclonalevolution                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Timefromthedateof firstdoseofstudy treatmenttothedateoffirstoocurrenceof anyof theclonalevolutioneventsup to year3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                  | Todeterminethephamacokineticsof eltrombopag inEast-AsiantreatmentnaiveSAA patients'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | PlasmaPKparametersandtrough concentrationofeltrombopagatsteady state                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Study design     | Non-randomized,openlabel,singleam,multi-center,Phasellstudy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Non-randomized,openlabel,singleam,multi-center,Phasellstudy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Rationale        | SAA is a life-threatening bone marrow failure disorder charactenzed by pancytopenia and hypocellularbonemarrow.DespiteitsrareincidenceintheWest.SAAismoreprevalentin denselypopulatedareasinEast-Asia.IST,comprisingr-ATGandCsA,isthefirst-line treatmentforSAApatientswhoareineligibleforHSCTinEast-Asiancountries.However. incompleteresponses.relapses,andprimaryrefractorinesslimitthesuccessofIsTand highlightstheunmetmedicalneed toimproveoutcomesfollowingfirst-lineISTinEast-Asian hematologicalresponsewithanacceptablesafetyprofile,inaphaseVllstudy（Studynumber: CETB115AUS01T).whereeltrombopagwasadministeredconcumentlywithh-ATGandCsAin ISTnaiveSAApatientsandinanotherphasell study（Studynumber:CETB115E1202)where eltrombopagwasadministered incombinationwithr-ATGandCsAinJapanesepatientswith moderateormoresevereaplasticanemiawhohavenotreceivedpriorATG/ALG-basedIST. Therefore,itisexpectedthatafavorablebenefiuriskprofilecanbedervedfromtheuseof | SAA is a life-threatening bone marrow failure disorder charactenzed by pancytopenia and hypocellularbonemarrow.DespiteitsrareincidenceintheWest.SAAismoreprevalentin denselypopulatedareasinEast-Asia.IST,comprisingr-ATGandCsA,isthefirst-line treatmentforSAApatientswhoareineligibleforHSCTinEast-Asiancountries.However. incompleteresponses.relapses,andprimaryrefractorinesslimitthesuccessofIsTand highlightstheunmetmedicalneed toimproveoutcomesfollowingfirst-lineISTinEast-Asian hematologicalresponsewithanacceptablesafetyprofile,inaphaseVllstudy（Studynumber: CETB115AUS01T).whereeltrombopagwasadministeredconcumentlywithh-ATGandCsAin ISTnaiveSAApatientsandinanotherphasell study（Studynumber:CETB115E1202)where eltrombopagwasadministered incombinationwithr-ATGandCsAinJapanesepatientswith moderateormoresevereaplasticanemiawhohavenotreceivedpriorATG/ALG-basedIST. Therefore,itisexpectedthatafavorablebenefiuriskprofilecanbedervedfromtheuseof |
| Study population | East-Asianadult andpediatricparticipants(26yearsold) withtreatment-naiveSAA who lackedasuitablematchedsiblingmarowdonororwerenotallogeneictransplantation candidatesduetoparticipantchoice,advancedage,orinfeasibilityoftransplantation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | East-Asianadult andpediatricparticipants(26yearsold) withtreatment-naiveSAA who lackedasuitablematchedsiblingmarowdonororwerenotallogeneictransplantation candidatesduetoparticipantchoice,advancedage,orinfeasibilityoftransplantation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

Table 2. Study treatment batch numbers

| Investigationall combination drug (nameandstrength)   | Pharmaceutical dosageform androuteof administration     | SupplyType                          | Batchnumbers                                  |
|-------------------------------------------------------|---------------------------------------------------------|-------------------------------------|-----------------------------------------------|
| Eltrombopag (ETB115)25mg                              | Tabletfororal use                                       | Openlabelparticipantpacks; bottles  | 2038615,2039746,2041381, 2043431              |
| Eltrombopag (ETB115)12.5mg                            | Tabletfororal use                                       | Openlabelparticipantpacks; bottles  | 2038616,2039747                               |
| r-ATG 25 mg                                           | Sterilelyophilized powderin10mL vialsfor intravenoususe | Openlabelparticipantpacks; vials    | AW0153,OW0727,AW4319, 9W2783                  |
| CsA25mg                                               | Capsulefororal use                                      | Openlabelparticipantpacks; blisters | KK8384,KX3464,LB3249 LE3766                   |
| CsA 5.0 g/50mL*                                       | Solutionfororal use                                     | Openlabelparticipantpacks; bottles  | China:Notavailable Othercountries:Localsupply |

TheCsAsolutionfromSandozisnotavailableinChina Source:Appendix16.1.1-Protocol-Table6-1,Appendix16.1.6

## Results

## Recruitment and baseline data

Overall, 36 participants were enrolled and treated in the study and of them, 8 participants were paediatric participants of &lt;18 years of age. Among the 8 paediatric participants, there were 4 participants each in the 6-11 years and 12-17 years age group, respectively (Table 3).

Table 3. Subject disposition by age subgroup &lt; 18 years (n=8). FAS

|                                     | All Subjects n (%)   |
|-------------------------------------|----------------------|
| Core Treatment Part                 |                      |
| Completed                           | 7 (87.5)             |
| Non responders at Week 26           | 1 (12.5)             |
| Responders (CR or PR) at Week 26    | 6 (75.0)             |
| Discontinued prematurely            | 1 (12.5)             |
| Reason for discontinuation          |                      |
| New therapy for study indication    | 1 (12.5)             |
| Subjects who entered Extension Part |                      |
| Completed                           | 6 (75.0)             |
| Ongoing                             | 0                    |
| Discontinued prematurely            | 0                    |
| Reason for discontinuation          |                      |

Core Treatment Part       : Study Day 1 to Week 26.

Extension Treatment Part  : Study Week 26 to Week 52.

Long-term Follow-up       : Study End of Treatment to Year 3.

- 4 subjects completed the core treatment part, but they didn't enter the extension part since they were assessed as nonresponder at week 26, as per protocol.

<div style=\"page-break-after: always\"></div>

Out of 8 participants, 7 (87.5%) completed the core treatment part at Week 26 (Responders = 6 the extension treatment phase (Week 52). Of the 7 participants (87.5%), who entered the long-term follow-up, 1 participant discontinued from the study due to guardian decision.

at least 1 dose adjustment. The reasons for dose adjustment were adverse event (n=1), disease improvement under study (n=1) and physician decision (n=1). There was a total of 4 dose interruptions was adverse event (n=2) [Study G2201 Final analysis CSRTable 14.3-1.4p].

participants; non responders = 1 participant). 1 participant (12.5%) discontinued the study treatment and subsequently initiated a new therapy for the disease. A total of 6 participants (75.0%), completed The median age in the 6-11 years age group (n=4) was 11 years (min-max: 9-11) and the majority of them were female (3 participants). There were 3 Japanese participants and 1 Chinese participant. The median weight of the participants was 33.2 kg (min-max: 27.6-42.4) [Study G2201 Primary analysis CSR-Table 14.1-2.1.1]. Three participants had SAA and 1 participant had VSAA. Four participants required platelet transfusion, and 3 participants required RBC transfusion due to their underlying disease. Median baseline values of platelet count, hemoglobin, absolute neutrophil count, and absolute reticulocyte count were 55.0 × 109/L, 90.0 g/L, 0.3 × 109/L, and 45 × 109/L, respectively [Study G2201 Primary analysis CSRTable 14.1-2.2.1]. The median age in the 12-17 years age group (n=4) was 16 years (min-max: 15-17) and the majority of them were female (3 participants). There were 2 Japanese participants and 2 Chinese participants. The median weight of the participants was 51.0 kg (min-max: 45.8-99.0) [Study G2201 Primary analysis CSR-Table 14.1-2.1.1]. Two participants had SAA and 2 participants had VSAA. Three participants required platelet transfusion, and 3 participants required RBC transfusion due to their underlying disease. Median baseline values of platelet count, hemoglobin, absolute neutrophil count, and absolute reticulocyte count were 25.0 × 109/L, 66.5 g/L, 0.2 × 109/L, and 7.1 × 109/L, respectively [Study G2201 Primary analysis CSRTable 14.1-2.2.1]. In participants &lt;18 years (N=8), the median duration of exposure for eltrombopag was 327.5 days (min-max: 115-365 days) and the median dose intensity was 37.5 mg/day (min-max: 33.3-75.0 mg/day). Seven participants (87.5%) were exposed to eltrombopag for a duration of &gt; 6-12 months and remaining 1 participant (12.5%) for a period 137 days [Study G2201 Final analysis CSR-Table 14.3-1.1p] [Study G2201 Final analysis CSR-Listing 16.2.5-1.1]. The median duration of exposure for CsA was 729.0 days (min-max: 142-752 days) and the median dose intensity was 214.1 mg/day (min-max: 140.1-229.4 mg/day). Three participants (37.5%) each were exposed to CsA for a duration of &gt; 18 - 24 months and &gt; 24 - 36 months respectively. One participant (12.5%) each were exposed to CsA for a duration of 3 - 6 months and &gt; 6 - 12 months respectively [Study G2201 Final analysis CSR-Table 14.3-1.2p]. The median duration of exposure for rATG was 5.0 days (min-max: 5-5 days) and the median dose intensity was 134.8 mg/day (min-max: 85.0-300.0 mg/day) [Study G2201 Final analysis CSRTable 14.3-1.3p]. There was a total of 6 dose adjustments in participants &lt;18 years of age, of which, 3 participants had interruptions, of which 3 participants had at least one interruption. The most common reason for dose

## Efficacy results

The standard criteria of CR as assessed by the Investigator was met by 2 participants (25.0%) at Week 26, of which, 1 participant each, was from 6-11 years and 12-17 years age group respectively [Study G2201 Primary analysis CSR-Table 11-2].

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Table11-2 (FAS)                                                                                                                                                                                                                                                                                                                                                                                                  | HematologicalresponseassessedbyInvestigatorbyassessmenttime Allparticipants                                                                                                                                                                                                                                                                                                                                      | HematologicalresponseassessedbyInvestigatorbyassessmenttime Allparticipants                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Assessmenttime Response                                                                                                                                                                                                                                                                                                                                                                                          | N=36 n(%)                                                                                                                                                                                                                                                                                                                                                                                                        | 95%C1                                                                                                                                                                                                                                                                                                                                                                                                            |
| Week13.toln                                                                                                                                                                                                                                                                                                                                                                                                      | 38                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Complete Response (CR)                                                                                                                                                                                                                                                                                                                                                                                           | 2(5.6)                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Parial Response(PR)                                                                                                                                                                                                                                                                                                                                                                                              | 22 (61.1)                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Noresponse/missedresponse                                                                                                                                                                                                                                                                                                                                                                                        | 12(33.3)                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Relapsed                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OverallResponseRate(ORR:CR+PR)                                                                                                                                                                                                                                                                                                                                                                                   | 24 (88.7)                                                                                                                                                                                                                                                                                                                                                                                                        | (49.0.81.4)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Week26,totaln                                                                                                                                                                                                                                                                                                                                                                                                    | 36                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Complete Response(CR)                                                                                                                                                                                                                                                                                                                                                                                            | 6(16.7)                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Partial Response(PR)                                                                                                                                                                                                                                                                                                                                                                                             | 22 (61.1)                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| No response/missedresponse                                                                                                                                                                                                                                                                                                                                                                                       | 8(22.2)                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Relapsed                                                                                                                                                                                                                                                                                                                                                                                                         | 0                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OverallResponseRate(ORR:CR+PR)                                                                                                                                                                                                                                                                                                                                                                                   | 28 (77.8)                                                                                                                                                                                                                                                                                                                                                                                                        | (60.8.89.9)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Week52.totaln                                                                                                                                                                                                                                                                                                                                                                                                    | 36                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Complete Response (CR) Partial Response(PR)                                                                                                                                                                                                                                                                                                                                                                      | 11 (30.6) 13 (36.1)                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Noresponse/missedresponse                                                                                                                                                                                                                                                                                                                                                                                        | 11 (30.6)                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Relapsed                                                                                                                                                                                                                                                                                                                                                                                                         | 1(2.8)                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OverallResponseRate(ORR:CR+PR)                                                                                                                                                                                                                                                                                                                                                                                   | 24 (68.7)                                                                                                                                                                                                                                                                                                                                                                                                        | (49.0.81.4)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Year2.totaln                                                                                                                                                                                                                                                                                                                                                                                                     | 38                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Complete Response(CR)                                                                                                                                                                                                                                                                                                                                                                                            | 11(30.6)                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Partial Response(PR) Noresponse/missedresponse                                                                                                                                                                                                                                                                                                                                                                   | 7(18.4) 16 (44.4)                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                  | 2(5.6)                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Relapsed网                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OverallResponseRate(ORR:CR+PR)                                                                                                                                                                                                                                                                                                                                                                                   | 18 (50.0)                                                                                                                                                                                                                                                                                                                                                                                                        | (32.9.67.1)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Year3.totaln                                                                                                                                                                                                                                                                                                                                                                                                     | 36                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Complete Response(CR)                                                                                                                                                                                                                                                                                                                                                                                            | 11(30.6)                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PartialResponse(PR)                                                                                                                                                                                                                                                                                                                                                                                              | 4(11.1)                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| No response/missedresponse                                                                                                                                                                                                                                                                                                                                                                                       | 10(528)                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| RelkosedR                                                                                                                                                                                                                                                                                                                                                                                                        | 2(5.6)                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                  |
| OverallResponseRate(ORR:CR+PR)                                                                                                                                                                                                                                                                                                                                                                                   | 15 (41.7)                                                                                                                                                                                                                                                                                                                                                                                                        | (25.5.50.2)                                                                                                                                                                                                                                                                                                                                                                                                      |
| n'isthenumberofparticipantswhoreachedtheassessmenttimeorwithdrewearlier.ltisdenominatorfor peroentage(%)calculation. llg5%confidenoeinterval (Cl) basedonClopper and Pearson(1934) binomial 95%。exactmethod. PThreerelaosesreportedbyYear2and Year3:the additional thirdparticipanthad'relapsedinfommation reportedintheresponseassessmenteCRF's'otherfieldinsteadofresponse'feld(duetouncertaindateof relapse). | n'isthenumberofparticipantswhoreachedtheassessmenttimeorwithdrewearlier.ltisdenominatorfor peroentage(%)calculation. llg5%confidenoeinterval (Cl) basedonClopper and Pearson(1934) binomial 95%。exactmethod. PThreerelaosesreportedbyYear2and Year3:the additional thirdparticipanthad'relapsedinfommation reportedintheresponseassessmenteCRF's'otherfieldinsteadofresponse'feld(duetouncertaindateof relapse). | n'isthenumberofparticipantswhoreachedtheassessmenttimeorwithdrewearlier.ltisdenominatorfor peroentage(%)calculation. llg5%confidenoeinterval (Cl) basedonClopper and Pearson(1934) binomial 95%。exactmethod. PThreerelaosesreportedbyYear2and Year3:the additional thirdparticipanthad'relapsedinfommation reportedintheresponseassessmenteCRF's'otherfieldinsteadofresponse'feld(duetouncertaindateof relapse). |

Supportive analysis that was derived programmatically was conducted for a more stringent definition of CR at Week 26 meeting all the criteria defined in [Study G2201 Final analysis CSR-Appendix 16.1.9Section 2.5.5]. 1 participant from the 12-17 years subgroup met the stringent criteria of CR at Week 26 [Study G2201 Primary analysis CSR-Table 14.2-1.4.1].

## Complete response rate at Week 13, Week 26, Week 52 and yearly after

The standard criteria of CR as assessed by the Investigator was met by [Study G2201 Final analysis CSR-Table 14.2-1.2p]:

- 1 participant (12.5%) (95% CI: 0.3, 52.7) at Week 13
- 2 participants (25.0%) (95% CI: 3.2, 65.1) at Week 26
- 4 participants (50.0%) (95% CI: 15.7, 84.3) at Week 52
- 4 participants (50.0%) (95% CI: 15.7, 84.3) at Year 2
- 5 participants (62.5%) (95% CI: 24.5, 91.5) at Year 3

<div style=\"page-break-after: always\"></div>

Table 14.2-1.2p. Study G2201 Final analysis

<!-- image -->

## Complete Response assessed by Investigator by assessment timeby Age subgroup Full Analysis Set

<!-- image -->

|                                                                                                                                                                                                  | All Subjects   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Subjects whoreached the week 13visit or withdrew earlier                                                                                                                                         | 8              |
| Complete response (CR) -n (%)                                                                                                                                                                    | 1(12.5)        |
| 95%, CI[1]                                                                                                                                                                                       | (0.3, 52.7)    |
| Subjects whoreached the week 26 visit or withdrew earier                                                                                                                                         | 8              |
| Complete response (CR)-n (%)                                                                                                                                                                     | 2 (25.0)       |
| 25%, CI[1]                                                                                                                                                                                       | (3.2, 65.1)    |
| Subjectswhoreachedtheweek52visitorwithdrewearlier                                                                                                                                                | 8              |
| Complete response (CR)-n (%)                                                                                                                                                                     | 4 (50.0)       |
| 95% CI[1]                                                                                                                                                                                        | (15.7,84.3)    |
| Subjectswhoreachedtheyear 2visitorwithdrewearlier                                                                                                                                                | 8              |
| Complete response (CR)-n (%)                                                                                                                                                                     | 4 (50.0)       |
| 05%0I[1]                                                                                                                                                                                         | (15.7. 84.3)   |
| Subjectswhoreached theyear3visit orwithdrewearlier                                                                                                                                               | 8              |
| Complete response (CR) -n (%)                                                                                                                                                                    | 5 (62.5)       |
| 95%CI[1]                                                                                                                                                                                         | (24.5, 91.5)   |
| Thedenominatorfor%calculation of CRwas the numberofsubjectswhoreached theassessment visit orwithdrewearlier. [1] 95%confidenceinlerval (Cl) based on Clopper andPearsonbinomial 95%exact method. |                |

## Overall response rate (CR+PR) at Week 13, Week 26, Week 52 and yearly after

Overall hematologic response rate (CR+PR), as assessed by the Investigator, was observed in:

- 6 participants (75.0%) (95% CI: 34.9, 96.8) at Week 13
- 6 participants (75.0%) (95% CI: 34.9, 96.8) at Week 26
- 6 participants (75.0%) (95% CI: 34.9, 96.8) at Week 52
- 5 participants (62.5%) (95% CI: 24.5, 91.5) at Year 2
- 6 participants (75.0%) (95% CI: 34.9, 96.8) at Year 3
- [Study G2201 Final analysis CSR-Table 14.2-1.3p]:

There was no relapse reported at any time during the study.

Table 14.2-1.3p. Overall haematological response rate at week 52, year 2 and year 3 in paediatric patients.

<!-- image -->

Full Analysis Set

<!-- image -->

| Assessment time Response           | All Subjects   | All Subjects   |
|------------------------------------|----------------|----------------|
| Assessment time Response           | n(%)           | 95%CI[1]       |
| Week 52, total n                   | 8              |                |
| Complete Response (CR)             | 4 (50.0)       |                |
| Partial Response (PR)              | 2(25.0)        |                |
| No Response (NR)                   | 2 (25.0)       |                |
| Relapse                            | 0              |                |
| Overall Response Rate (ORR: CR+PR) | 6(75.0)        | (34.9, 96.8)   |
| Year 2. total n                    | 8              |                |
| Complete Response (CR)             | 4 (50.0)       |                |
| Partial Response (PR)              | 1(12.5)        |                |
| No Response (NR)                   | 3(37.5)        |                |
| Relapse                            | 0              |                |
| OverallResponseRate(ORR:CR+PR)     | 5 (62.5)       | (24.5. 91.5)   |
| Year 3. total n                    | 8              |                |
| CompleteResponse(CR)               | 5 (62.5)       |                |
| Partial Response (PR)              | 1(12.5)        |                |
| No Response (NR)                   | 2 (25.0)       |                |
| Relapse                            | 0              |                |
| OverallResponseRate(ORR:CR+PR)     | 6 (75.0)       | (34.9, 96.8)   |

<div style=\"page-break-after: always\"></div>

## Duration of response

The median duration of CR (derived programmatically) for the 4 participants who were complete responders at any time during the study was not evaluable. All 4 participants who were complete responders at Week 52 were still responding without any documented relapses at Year 3 [Study G2201 Final analysis CSR-Table 14.2-2.1p].

The median duration of overall response (derived programmatically) for the 6 participants who were overall responders at any time during the study was not achieved from the analysis. 4/6 participants were still responding at last contact with study (either at Year 3 visit or last contact before discontinuation), and 2/6 participants were considered relapsed programmatically as they showed no hematological response. The KM estimated probability of relapse-free time at 30 months was 66.7% (95% CI: 19.5, 90.4) [Study G2201 Final analysis CSR-Table 14.2-2.2p].

Even though 2 participants showed no hematological response (identified as relapsed programmatically), these participants were assessed as PR at Week 26 by Investigators [Study G2201 Final analysis CSR-Listing 16.2.6-1.2] [Study G2201 Final analysis CSRListing 16.2.8-1.1].

<!-- image -->

<!-- image -->

<!-- image -->

|                                                            | All Subjects   |
|------------------------------------------------------------|----------------|
| Numberofcompleterespondersatanytime                        | 4              |
| Relapsed                                                   | 0              |
| Still responding                                           | 4(100)         |
| Cngong                                                     | 4(100)         |
| Lost tofollow-up                                           | 0              |
| Duration of completeresponseinmonths-Percentles(95%,Cl)[1] |                |
| 25th                                                       | NE(NE NE)      |
| 50th                                                       | NE(NE,NE)      |
| 75th                                                       | NE(NE,NE)      |
| Relapse-feeprcbabiity estimates(@5%Cl)[2]                  |                |
| 6Months                                                    | 100（100.100）   |
| 12Months                                                   | 100(100.100)   |
| 18Months                                                   | 100(100,100)   |
| 24Months                                                   | 100 (100,100)  |
| 30Months                                                   | 100(100,100)   |
| 38Months                                                   | NE(NE,NE)      |

2]Relapse-freeprobabityestimateistheestimatedprobabiltythatapatientwillremainrelapse-freeupto thespecifiedtmepoint.

[1]Percentieswith95%Clsarecalculated fromPROCLIFETESToutputusingmethodofBrookmeyerandCrowey.

Relapse-freeprobabilityestimatesareobtainedfromtheKanfan-Meiersurvivalestimates.GreenwoodfomulaisusedforCisofKMestimates.

-NE=Notestimable

where thelog-logIinkfunctionisused.

-Relapse:Relapsespecificallyrefers tothe lossof CompleteResponse

-LosttoFolow-up:PatentsrenainedCRwithoutfurtherinvestigatorassessmentduetoprematurediscontinuationorlosttofollow-upbeforeYear3

-Ongoing:PabentsremainedCR atthelastplarned investigatorassessment(Year3)

## Overall survival

There were no deaths reported during the study. The median duration of OS was not evaluable from the KM analysis. The KM estimated probability of survival at 36 months was 100.0%

(95% CI: 100.0, 100.0) [Study G2201 Final analysis CSR-Table 14.2-2.3p].

<div style=\"page-break-after: always\"></div>

## Transfusion-free interval (packed RBC and platelet) before Week 13 and Week 26

The median RBC transfusion-free interval was 26.0 days (min-max: 4-92 days) before Week 13 and 117.0 days (min-max: 14-183 days) before Week 26 [Study G2201 Primary analysis CSRTable14.2-2.4.1]. The median platelet transfusion-free interval was 26.5 days (min-max: 2-66 days) before Week 13 and 131.0 days (min-max: 6-157 days) before Week 26 [Study G2201 Primary analysis CSR-Table-14.2-2.4.1].

## Proportion of participants who become (packed RBC/platelet) transfusion independent RBC transfusion independent

Out of 6 participants who had transfusion dependency at baseline, 4 participants achieved transfusion independence post-baseline (transfusion free for a period of at least 56 days) [Study G2201 Final analysis CSR-Table 14.2-2.8p].

The proportion of RBC transfusion dependent participants at baseline, showing ≥ 50% transfusion decrease or becoming transfusion free increased from 2 participants at Week 13 to 4 participants at Week 26 and remained at 4 participants for Week 52, Week 104 and Week 156 respectively [Study G2201 Final analysis CSR-Table 14.2-2.6p].

## Platelet transfusion independent

Out of 7 participants who had transfusion dependency at baseline, 5 participants achieved transfusion independence post-baseline (transfusion free for a period of at least 28 days) [Study G2201 Final analysis CSR-Table 14.2-2.7p].

The proportion of participants (who were platelet transfusion dependent at baseline) showing a transfusion decrease (or free) was 6 participants at Week 13, 6 participants at Week 26, 5 participants at Week 52, 4 participants at Week 104 and 5 participants at Week 156 [Study G2201 Final analysis CSR-Table 14.2-2.5p].

The proportion of platelet transfusion dependent participants showing a ≥ 50% transfusion reduction compared to baseline was 3 participants at Week 13, 6 participants at Week 26, 5 participants at Week 52, 4 participants at Week 104 and 5 participants at Week 156 [Study G2201 Final analysis CSR-Table 14.2-2.5p].

## Changes in platelet count, hemoglobin, and neutrophil count in absence of transfusion and changes in reticulocyte count from baseline

An improvement in platelet count (in the absence of platelet transfusion), hemoglobin levels (in the absence of RBC transfusion), neutrophil count (in the absence of G-CSF) and reticulocyte count was observed for all participants (n=8) at Week 13 compared to baseline. The trend continued at Week 26, Week 52 and during long term follow-up (Year 2 and Year 3 respectively).

<div style=\"page-break-after: always\"></div>

Median platelet count increased from 42.5 × 109/L at baseline to 58.0 × 109/L, 86.5 × 109/L, 133.5 × 109/L, 148.0 × 109/L, and 148.5 × 109/L at Week 13, Week 26, Week 52, Year 2, and Year 3 respectively [Study G2201 Final analysis CSR-Table 14.2-2.12p].

Median hemoglobin increased from 78.0 g/L at baseline to 91.0 g/L, 112.5 g/L, 110.5 g/L, 124.0 g/L, and 136.0 g/L at Week 13, Week 26, Week 52, Year 2, and Year 3 respectively [Study G2201 Final analysis CSR-Table 14.2-2.13p].

Median neutrophil count increased from 0.3 × 109/L at baseline to 1.1 × 109/L, 1.7 × 109/L, 1.9 × 109/L, 2.2 × 109/L, and 2.8 × 109/L at Week 13, Week 26, Week 52, Year 2 and Year 3 respectively [Study G2201 Final analysis CSR-Table 14.2-2.14p].

Median absolute reticulocyte count increased from 11.5 × 109/L at baseline to 82.3 × 109/L, 48.0 × 109/L, 51.7 × 109/L, 64.7 × 109/L, and 72.5 × 109/L at Week 13, Week 26, Week 52, Year 2 and Year 3 respectively [Study G2201 Final analysis CSR-Table 14.2-2.15p].

## Safety results

## Overview of adverse events

An overview of the adverse events is presented in Table 4.

| Category                                | All Subjects N=8 Allgrades n (%)   | Grade>=3 n (%)   |
|-----------------------------------------|------------------------------------|------------------|
| Adverseevents                           | 8 (100)                            | 5 (62.5)         |
| Suspected toberelaled toeltrombopag     | 7 (87.5)                           | 4 (50.0)         |
| Suspected toberelatedtostucy lreatment  | 8(100)                             | 5 (62.5)         |
| SAEs                                    | 3 (37.5)                           | 3(37.5)          |
| Suspected toberelated toeltrombopag     | 1 (12.5)                           | 1(12.5)          |
| Suspected toberelated tostucy treatment | 2 (25.0)                           | 2 (25.0)         |
| FatalSAEs                               | 0                                  | 0                |
| AEsleadingtodiscontinuation             |                                    | 0                |
| AEsleadingtodoseadjustmentinterruption  | 6 (75.0)                           | 2 (25.0)         |
| Suspeoted to berelaled to eltrombopag   | 2 (25.0)                           | 0                |
| Suspected toberelated tostudy treatment | 6 (75.0)                           | 1(12.5)          |
| AEsrequiringadditionaltherapy           | 8 (100)                            | 5 (62.5)         |
| Suspected toberelated toeltrombopag     | 4 (50.0)                           | 2 (25.0)         |
| Suspected toberelated tostudy treatment | 8 (100)                            | 5(62.5)          |

Numbers(n)representcountsofsubjects.

AEsoooumingduningtreatmentorwithin30daysofthelastdoseofeltrombopagaresummarized. AsubjectwithmultipleseveritygradesforanAEisonlycountedunderthemaximumgrade.

MedDRAversion27.1.CTCAEversion4.03.

Source:[StudyG2201FinalanalysisCSR-Table14.3.1-1.1p]

<div style=\"page-break-after: always\"></div>

## Analysis of adverse events

The most reported AEs by PT (&gt; 30% of participants) were constipation, stomatitis, pyrexia and ALT increased (each in 4 participants, 50.0%). This was followed by vomiting, hypertension, hyperuricaemia and febrile neutropenia (each in 3 participants, 37.5% ). The most reported ≥ Grade 3 AEs by PT (≥ 25% of participants) were febrile neutropenia (3 participants, 37.5%) followed by ALT increased and serum sickness (each in 2 participants, 25.0%) [Study G2201 Final analysis CSR-Table 14.3.1-1.2p].

All participants (n=8) experienced at least one on-treatment AE in the first 30 days of eltrombopag treatment; there was no trend of increasing frequency observed with any of the reported AEs over time (time period of onset includes &gt; 30 to ≤ 90 days, &gt; 90 to ≤ 180 days, &gt; 180 to ≤ 360 days) [Study G2201 Final analysis CSR-Table 14.3.1-1.2.2p].

The most reported AEs (≥ 25.0% of participants) suspected by the Investigator to be related to study treatment (study treatment included any of the following: eltrombopag, r-ATG, CsA, or combination of these drugs up to the end of Year 2) were ALT increased and hyperuricaemia, (each in 3 participants, 37.5%). This was followed by febrile neutropenia, vomiting, serum sickness, hypersensitivity, pyrexia, cytomegalovirus infection reactivation, renal impairment and hypertension (each in 2 participants, 25.0%). The most reported ≥ Grade 3 AEs suspected by the Investigator to be related to study treatment were febrile neutropenia and serum sickness, (each in 2 participants, 25.0%) [Study G2201 Final analysis CSR-Table 14.3.1-1.4p].

The most reported AEs (≥ 25.0% of participants) suspected by the Investigator to be related to eltrombopag were ALT increased (3 participants, 37.5%) and hyperuricaemia (2 participants, 25.0%). AEs (≥ Grade 3) suspected by the Investigator to be related to eltrombopag were ALT increased, blood alkaline phosphatase increased, lipase increased and hyperuricaemia (each in 1 participant, 12.5%) [Study G2201 Final analysis CSR-Table 14.3.1-1.4.3p].

## Death

There were no deaths reported during the study [Study G2201 Final analysis CSR-Listing 16.2.7-1.3].

## Serious adverse events

The reported SAEs by PT were herpes zoster, sepsis, hyperuricemia (each in 1 participant, 12.5%) for both all grades and ≥ Grade 3, respectively [Study G2201 Final analysis CSR-Table 14.3.1-1.5p].

Among the reported SAEs, hyperuricaemia was suspected by the investigator to be related to eltrombopag. As of the LPLV date (06-Dec-2024), the reported SAEs were recovered/resolved in all the participants [Study G2201 Final analysis CSR-Listing 16.2.7-1.1].

## Adverse events leading to discontinuation

There were no AEs reported that led to discontinuation of participants [Study G2201 Final analysis CSR- Table 14.3.1-1.6p].

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

Hepatotoxicity: Hepatotoxicity was reported in 7 participants (87.5%). The most reported hepatotoxicity related events (≥ 25% of participants) were ALT increased (4 participants, 50.0%) followed by AST increased, blood bilirubin increased, GGT increased (each in 2 participants, 25.0%).

Hyperbilirubinemia was reported in 1 participant (12.5%). Grade 3 hepatotoxicity related events were reported for 3 participants (37.5%) during the study. Hepatotoxicity related events that were suspected by the Investigator to be related to eltrombopag treatment were reported in 6 participants (75.0%). Eltrombopag treatment was interrupted in 2 participants (25.0%). 4 participants (50.0%) required additional medication/therapy due to these events. None of the reported hepatotoxicity related events were serious, fatal or led to eltrombopag withdrawal. As of the LPLV date (06-Dec2024), the hepatotoxicity related events were recovered/resolved in 6 participants (75.0%) [Study G2201 Final analysis CSR-Table 14.3.1-3.1p].

Acute kidney injury: Acute kidney injury was reported in 5 participants (62.5%). The reported AKI related events were blood creatinine increased and renal impairment (each in 2 participants, 25.0%), followed by blood urea increased, acute kidney injury and renal failure (each in 1 participant, 12.5%).

None of the reported AKI related events were suspected by the Investigator to be related to eltrombopag treatment. None of the reported AKI related events were ≥ Grade 3, serious, fatal or led to eltrombopag withdrawal/interruption. Only 1 participant (12.5%) required additional medication/therapy due to these events. As of the LPLV date (06-Dec-2024), the AKI related events were resolved in all 5 participants (62.5%) [Study G2201 Final analysis CSR-Table 14.3.1-3.9p].

Thromboembolic events: There were no cases of thromboembolic events reported during the study [Study G2201 Final analysis CSR-Table 14.3.1-3.3p].

## Clonal evolution/cytogenetic abnormality and haematological malignancy events

There was 1 clonal evolution/cytogenetic abnormality AESIs reported during the post-treatment followup period [Study G2201 Final analysis CSR -Listing 16.2.5-1.1], [Study G2201 Final analysis CSRListing 16.2.7-1.1], [Study G2201 Final analysis CSR-Listing 16.2.8-1.6], [Study G2201 Final analysis CSR-Listing 16.2.8-1.7]. The participant reported CHR8 abnormalities (in 3% of cells examined) at an unscheduled visit 187 days after last dose of eltrombopag.

Follow-up cytogenic FISH analysis reported normal CHR8 results; the reported cytogenic abnormality AE was reported as resolved after 16 days. There were no cases of haematological malignancies.

One participant reported cytogenetic abnormalities (as assessed by karyotype) that were not considered clinically significant and/or did not lead to clonal evolution/cytogenetic abnormality or hematological malignancy related events. The participant reported 46, XX, del(20q) in 1 out of 20 metaphases at Week 156 [Study G2201 Final analysis CSR-Listing 16.2.8-1.6].

Bone marrow fibrosis was reported in 1 participant at screening and Week 13 visit. However, there was no fibrosis observed at Week 26 [Study G2201 Final analysis CSR-Listing 16.2.8-1.5].

## 2.3.3. Discussion on clinical aspects

The MAH has provided limited data on long-term efficacy (up to week 26 for primary assessment and up to 3 years for secondary assessment) in 8 Asian paediatric participants with treatment-naïve severe

<div style=\"page-break-after: always\"></div>

aplastic anaemia in study G2201. A CR rate of 12.5%, as observed by the Investigator at Week 13, improved to 25.0% at Week 26. The CR further improved and remained at 50.0% at Week 52 and Year 2. At Year 3, the CR rate was 62.5%. All 4 participants who were complete responders at any time were still responding without any documented relapses at Year 3. The overall haematological response rate as observed by the Investigator was consistent and remained at 75.0% from Week 13 up to Week 52 and at Year 3. The rate dropped to 62.5% at Year 2 alone.

Treatment with eltrombopag tended to prolong the transfusion-free interval of packed RBC and platelets and increased the proportion of paediatric participants who became packed RBC and platelet transfusion independent. An improvement relative to baseline was observed in Platelet, neutrophil and reticulocyte counts, and haemoglobin levels at Week 26, Week 52 and during long-term follow-up. However, the data are too scarce to draw any meaningful conclusion.

The safety profile of eltrombopag in paediatric participants was consistent with the established safety profile. No new safety signals were detected. There were no deaths reported during the study. The median duration of OS was not evaluable from the KM analysis. The KM estimated probability of survival at 36 months was 100.0% (95% CI: 100.0, 100.0)

Based on the final results of Study CETB115G2201, the benefit-risk profile of eltrombopag in the approved indications remains unchanged and no changes to the approved Summary of Characteristics are proposed.

The rapporteur agrees with the MAH that no further action is required.

## 3. Rapporteur's overall conclusion and recommendation

<!-- image -->

## Fulfilled:

No regulatory action required.